{"transactions":[{"id":860670,"issuer":{"id":8048,"kind":"organization","name":"CNS Pharmaceuticals, Inc."},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-04T17:01:43.000Z","date":"2026-03-02","kind":"grant","planned":false,"acquired":true,"shares":9500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Company common stock."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Issued in connection with the reporting person's employment with the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units set forth in the table vest as follows: 25% on the six-month anniversary of the transaction date, 25% on the twelve-month anniversary of the transaction date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date."}],"balance_after":9500,"derivative":{"expiration_date":"2036-03-02","underlying":"Common Stock","underlying_shares":9500},"source":{"system":"sec-edgar","filing":"0001683168-26-001489","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1615840/000168316826001489/ownership.xml","form_type":"4"}},{"id":1182787,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:20:36.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":253123,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":5,"expiration_date":"2033-12-28","underlying":"Common Stock","underlying_shares":253123},"source":{"system":"sec-edgar","filing":"0001213900-25-028225","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390025028225/ownership.xml","form_type":"4"}},{"id":1182786,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:20:36.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":256438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":4.96,"expiration_date":"2032-07-01","underlying":"Common Stock","underlying_shares":256438},"source":{"system":"sec-edgar","filing":"0001213900-25-028225","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390025028225/ownership.xml","form_type":"4"}},{"id":1182785,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:20:36.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":107463,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":6.07,"expiration_date":"2031-09-01","underlying":"Common Stock","underlying_shares":107463},"source":{"system":"sec-edgar","filing":"0001213900-25-028225","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390025028225/ownership.xml","form_type":"4"}},{"id":1182784,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:20:36.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":59066,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":9.55,"expiration_date":"2030-08-12","underlying":"Common Stock","underlying_shares":59066},"source":{"system":"sec-edgar","filing":"0001213900-25-028225","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390025028225/ownership.xml","form_type":"4"}},{"id":1182783,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:20:36.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":6.96,"expiration_date":"2029-07-12","underlying":"Common Stock","underlying_shares":13333},"source":{"system":"sec-edgar","filing":"0001213900-25-028225","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390025028225/ownership.xml","form_type":"4"}},{"id":1182782,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:20:36.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8833,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":23.49,"expiration_date":"2028-07-13","underlying":"Common Stock","underlying_shares":8833},"source":{"system":"sec-edgar","filing":"0001213900-25-028225","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390025028225/ownership.xml","form_type":"4"}},{"id":1182781,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:20:36.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":41.7,"expiration_date":"2027-03-14","underlying":"Common Stock","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0001213900-25-028225","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390025028225/ownership.xml","form_type":"4"}},{"id":1182780,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:20:36.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":59.7,"expiration_date":"2026-04-14","underlying":"Common Stock","underlying_shares":1666},"source":{"system":"sec-edgar","filing":"0001213900-25-028225","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390025028225/ownership.xml","form_type":"4"}},{"id":1182779,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-02T22:20:36.000Z","date":"2025-03-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, effective March 31, 2025, in exchange for nominal consideration."}],"balance_after":0,"derivative":{"exercise_price":53.7,"expiration_date":"2025-10-01","underlying":"Common Stock","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0001213900-25-028225","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390025028225/ownership.xml","form_type":"4"}},{"id":1697776,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-12-29T22:20:23.000Z","date":"2023-12-28","kind":"grant","planned":false,"acquired":true,"shares":253123,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This price represents the closing price of the Issuer's common stock on December 28, 2023, the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Issuer's 2019 Stock Plan, 2% of the options will vest each month from the date of grant until fully vested."}],"balance_after":253123,"derivative":{"exercise_price":5,"expiration_date":"2033-12-28","underlying":"Common Stock","underlying_shares":253123},"source":{"system":"sec-edgar","filing":"0001213900-23-100077","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390023100077/ownership.xml","form_type":"4"}},{"id":2216800,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-01T23:19:32.000Z","date":"2022-07-01","kind":"grant","acquired":true,"shares":256438,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This price represents the closing price of the Company's common stock on July 1, 2022, the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Company's 2019 Stock Plan, 2% of the options will vest each month from July 1, 2022 until fully vested."}],"balance_after":256348,"derivative":{"exercise_price":4.96,"expiration_date":"2032-07-01","underlying":"Common Stock","underlying_shares":256438},"source":{"system":"sec-edgar","filing":"0001213900-22-036877","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390022036877/ownership.xml","form_type":"4"}},{"id":2578643,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-09-03T21:02:57.000Z","date":"2021-09-01","kind":"grant","acquired":true,"shares":107463,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from September 1, 2021 until fully vested."}],"balance_after":107463,"derivative":{"exercise_price":6.07,"expiration_date":"2031-09-01","underlying":"Common Stock","underlying_shares":107463},"source":{"system":"sec-edgar","filing":"0001213900-21-046684","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390021046684/ownership.xml","form_type":"4"}},{"id":3057011,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-14T21:21:47.000Z","date":"2020-08-12","kind":"grant","acquired":true,"shares":59066,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This price represents the closing price of the Company's common stock on the date of the board of directors approval of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Company's Amended and Restated 2013 Stock Plan and 2019 Stock Plan, 2% of the options will vest each month from August 12, 2020 until fully vested."}],"balance_after":59066,"derivative":{"exercise_price":9.55,"expiration_date":"2030-08-12","underlying":"Common Stock","underlying_shares":59066},"source":{"system":"sec-edgar","filing":"0001213900-20-022342","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390020022342/ownership.xml","form_type":"4"}},{"id":3460574,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Options to purchase common stock","published_at":"2019-07-16T21:10:19.000Z","date":"2019-07-12","kind":"grant","acquired":true,"shares":400000,"price":0.232,"value":92800.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant."}],"balance_after":400000,"derivative":{"exercise_price":0.232,"exercise_date":"2019-07-12","expiration_date":"2029-07-12","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001213900-19-012881","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390019012881/ownership.xml","form_type":"4"}},{"id":3737257,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Common Stock","published_at":"2018-12-10T21:10:37.000Z","date":"2018-12-10","kind":"purchase","acquired":true,"shares":10000,"price":0.435,"value":4350.0,"ownership":{"direct":true},"balance_after":35500,"source":{"system":"sec-edgar","filing":"0001213900-18-017143","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390018017143/ownership.xml","form_type":"4"}},{"id":3865994,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Options to purchase common stock","published_at":"2018-07-17T21:11:06.000Z","date":"2018-07-13","kind":"grant","acquired":true,"shares":265000,"price":0.7829,"value":207468.5,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options vest each month from the date of grant."}],"balance_after":265000,"derivative":{"exercise_price":0.7829,"exercise_date":"2018-07-13","expiration_date":"2028-07-13","underlying":"Common Stock","underlying_shares":265000},"source":{"system":"sec-edgar","filing":"0001213900-18-009315","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390018009315/ownership.xml","form_type":"4"}},{"id":3892152,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-15T22:08:11.000Z","date":"2018-06-15","kind":"purchase","acquired":true,"shares":12000,"price":0.5,"value":6000.0,"ownership":{"direct":true},"balance_after":25500,"source":{"system":"sec-edgar","filing":"0001213900-18-007754","document":"f4061518oloughlin_actinium.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390018007754/f4061518oloughlin_actinium.xml","form_type":"4"}},{"id":4004979,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Series B Warrants","published_at":"2018-03-08T21:20:37.000Z","date":"2018-03-06","kind":"other","acquired":true,"shares":7500,"price":0.5,"value":3750.0,"ownership":{"direct":true},"balance_after":7500,"derivative":{"exercise_price":0.7,"exercise_date":"2018-03-06","expiration_date":"2020-09-06","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-18-002726","document":"f4030618oloughlin_actinium.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390018002726/f4030618oloughlin_actinium.xml","form_type":"4"}},{"id":4004978,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Series A Warrants","published_at":"2018-03-08T21:20:37.000Z","date":"2018-03-06","kind":"other","acquired":true,"shares":2500,"price":0.5,"value":1250.0,"ownership":{"direct":true},"balance_after":2500,"derivative":{"exercise_price":0.6,"exercise_date":"2018-03-06","expiration_date":"2019-03-06","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001213900-18-002726","document":"f4030618oloughlin_actinium.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390018002726/f4030618oloughlin_actinium.xml","form_type":"4"}},{"id":4004977,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Common Stock","published_at":"2018-03-08T21:20:37.000Z","date":"2018-03-06","kind":"other","acquired":true,"shares":10000,"price":0.5,"value":5000.0,"ownership":{"direct":true},"balance_after":13500,"source":{"system":"sec-edgar","filing":"0001213900-18-002726","document":"f4030618oloughlin_actinium.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390018002726/f4030618oloughlin_actinium.xml","form_type":"4"}},{"id":4280392,"issuer":{"id":7435,"kind":"organization","name":"Actinium Pharmaceuticals, Inc.","symbol":"ATNM"},"owners":[{"id":62755,"kind":"person","name":"O'Loughlin Steve","position":1,"cik":"0001615840","reported_name":"O'Loughlin Steve","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Financial Officer"}}],"security":"Common stock","published_at":"2017-06-15T20:51:34.000Z","date":"2017-06-15","kind":"purchase","acquired":true,"shares":3500,"price":1.17,"value":4095.0,"ownership":{"direct":true},"balance_after":3500,"source":{"system":"sec-edgar","filing":"0001213900-17-006527","document":"f4061517oloughlin_actinium.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390017006527/f4061517oloughlin_actinium.xml","form_type":"4"}}]}